Ray Dalio’s NVO Holdings & Trades

First Buy
Q3 2025
Duration Held
1 Quarters
Largest Add
Q3 2025
+138,947 shares
Current Position
138,947 shares
$7.71 M value

Ray Dalio's NVO Position Overview

Ray Dalio (via Bridgewater Associates, Lp) currently holds 138.9K shares of Novo Nordisk A/S (NVO) worth $7.71 M, representing 0.03% of the portfolio. First purchased in 2025-Q3, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Ray Dalio has initiated a new position in NVO, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Ray Dalio's Novo Nordisk A/S (NVO) Holding Value Over Time

Track share changes against reported price movement

Quarterly Novo Nordisk A/S (NVO) Trades by Ray Dalio

Period Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q3 2025 +138,947 New Buy 138,947 $55.49

Ray Dalio's Novo Nordisk A/S Investment FAQs

Ray Dalio first purchased Novo Nordisk A/S (NVO) in Q3 2025, acquiring 138,947 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Ray Dalio has held Novo Nordisk A/S (NVO) for 1 quarters since Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Ray Dalio's largest addition to Novo Nordisk A/S (NVO) was in Q3 2025, adding 138,947 shares worth $7.71 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

According to the latest 13F filing for Q3 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 138,947 shares of Novo Nordisk A/S (NVO), valued at approximately $7.71 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

As of the Q3 2025 filing, Novo Nordisk A/S (NVO) represents approximately 0.03% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Ray Dalio's peak holding in Novo Nordisk A/S (NVO) was 138,947 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.